Table 1.
Clinical data between remote and outpatient programming group.
| Remote programming group n = 27 |
Outpatient Programming group n = 47 |
P | |
|---|---|---|---|
| Gender (M/F) | 15/12 | 21/26 | 0.368a |
| Age (years) | 60.77 ± 0.6 | 61.16 ± 0.6 | 0.810b |
| Course of disease (years) | 9.24 ± 0.2 | 12.17 ± 0.3 | 0.061b |
| Hoehn-Yahr stage (X ± S) | 3.20 ± 0.7 | 3.40 ± 0.8 | 0.387b |
| Pre-op. LEDD (mg) | 688.0 (450.0–825.0) | 600.0 (400.0–831.0) | 0.363c |
| Decrease rate of LEDD (%)d | 46.0 (31.0–58.0) | 33.0 (8.0–57.0) | 0.368c |
| Pre-op. MUPDRS III (medicine-off) | 29.0 (24.0–35.0) | 32.0 (25.0–45.0) | 0.157c |
| Improvement rate of MUPDRS III (%)e | 64.02 ± 0.0 | 65.71 ± 7.5 | 0.692b |
| Distance from residence to programming center (km) | 100.0 (14.0–228.0) | 20.0 (15.0–150.0) | 0.381c |
| Residence (Wuhan/other regions) | 9/18 | 27/20 | 0.046a |
LEDD, Levodopa Equivalent Daily Dose; MUPDRS III, Modified Unified Parkinson's Disease Rating Scale III;
a
χ2 test;
b
Independent sample t-test;
c
Wilcoxon rank-sum test;
d
(per-op. LEDD – LEDD at the last follow-up) / pre-op.
LEDD * 100%;
e
(pre-op. MUPDRS III – MUPDRS III at the last follow-up) / per-op.
MUPDRS III * 100%. MUPDRS III at the last follow-up was performed with medicine-off, stimulation-on.